Research output per year
Research output per year
Personal profile
Research interests
Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. One of our major focuses is the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 20-25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches. Proteomics is the large-scale identification and characterization of proteins and it can be used to provide deeper insights into these pathways by identifying novel proteins and sites of post-translational modifications. We have previously published a large proteomic study of Her2/neu signaling in cell lines and are currently working on performing proteomic experiments in animal models.
Clinical interests
Breast cancer, HER2 positive breast cancer, oncology, medical oncology
Available to Mentor:
- PhD/MSTP Students
Fingerprint
Dive into the research topics where Ron Bose is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab 1 Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors
Sweeney, C. J., Hainsworth, J. D., Bose, R., Burris, H. A., Kurzrock, R., Swanton, C., Friedman, C. F., Spigel, D. R., Szado, T., Schulze, K., Price, R., Malato, J., Lo, A. A., Levy, J., Wang, Y., Yu, W. & Meric-Bernstam, F., Jan 20 2024, In: Journal of Clinical Oncology. 42, 3, p. 258-265 8 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A., Achilefu, S., Hagemann, I. S., Edwards, J. R. & Bose, R., Sep 2023, In: Cancer research. 83, 17, p. 2839-2857 19 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Chan, A., Ruiz-Borrego, M., Marx, G., Chien, A. J., Rugo, H. S., Brufsky, A., Thirlwell, M., Trudeau, M., Bose, R., García-Sáenz, J. A., Egle, D., Pistilli, B., Wassermann, J., Cheong, K. A., Schnappauf, B., Semsek, D., Singer, C. F., Foruzan, N., DiPrimeo, D. & McCulloch, L. & 2 others, , Feb 2023, In: Breast. 67, p. 94-101 8 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations -
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Hensing, W. L., Gerratana, L., Clifton, K., Medford, A. J., Velimirovic, M., Shah, A. N., Amico, P. D., Reduzzi, C., Zhang, Q., Dai, C. S., Denault, E. N., Bagegni, N. A., Opyrchal, M., Ademuyiwa, F. O., Bose, R., Behdad, A., Ma, C. X., Bardia, A., Cristofanilli, M. & Davis, A. A., Aug 15 2023, In: Clinical Cancer Research. 29, 16, p. 3092-3100 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Jhaveri, K., Eli, L. D., Wildiers, H., Hurvitz, S. A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E. S., Spanggaard, I., Reid, S., Burkard, M. E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F. C., Loi, S., Crown, J. & Bhave, M. & 22 others, , Oct 2023, In: Annals of Oncology. 34, 10, p. 885-898 14 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations